Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Bacterial infections

Cefiderocol effective for carbapenem-resistant Gram-negative infections

Researchers have concluded that cefiderocol can be used to treat patients with carbapenem-resistant infections, who have limited treatment options.

Carbapenem resistant bacteria acinetobacter spp

Source: Phanie / Alamy Stock Photo

In the study, more patients in the cefiderocol group died; however, this was mainly noted to be in patients with pneumonia or bloodstream infections, or sepsis caused by Acinetobacter spp (pictured)

The clinical and microbiological outcomes of cefiderocol, a new antibiotic, were similar to the best available therapy for patients with life-threatening carbapenem-resistant infections, a phase III study has suggested (12 October 2020)[1].

Researchers randomly assigned 152 patients with infections caused by carbapenem-resistant Gram-negative bacteria to either cefiderocol (85% received monotherapy), or best available therapy (61% received combination therapy). 

The findings showed that clinical and microbiological outcomes by site of infection or causative pathogen were similar between the two groups.

However, more patients in the cefiderocol group died than in the best available therapy group (34 [34%] of 101 vs 9 [18%] of 49). This difference was mainly noted in patients with pneumonia or bloodstream infections, or sepsis caused by Acinetobacter spp.

The researchers highlighted several possible reasons for this; one of which was that it was a chance finding owing to the low study numbers. In addition, more patients in the cefiderocol group had been in a state of shock or in intensive care at randomisation, indicating a higher baseline mortality risk. The low mortality rate among the best available therapy group also seemed to be an outlier compared with other studies.

“Collectively, the findings from this study support cefiderocol as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208485

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.